Takeda Pharmaceutical Company Limited (FRA:TKD)

Market Cap	38.60B
Revenue (ttm)	25.44B
Net Income (ttm)	190.49M
Shares Out	n/a
EPS (ttm)	0.12
PE Ratio	202.63
Forward PE	n/a
Dividend	1.17 (4.85%)
Ex-Dividend Date	Sep 29, 2025

Volume	n/a
Average Volume	175
Open	24.21
Previous Close	24.18
Day's Range	24.21 - 24.21
52-Week Range	22.45 - 28.29
Beta	n/a
RSI	49.98
Earnings Date	Jan 29, 2026

About FRA:TKD

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A...

• Industry: Pharmaceutical Preparations
• Founded: 1781
• Employees: 47,455
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TKD

Financial Performance

In 2024, FRA:TKD's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY